Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
Recent posts
-
The United States is investing billions of dollars to get doctors to use electronic health records for patients at their practices. Why then, Phreesia CEO Chaim Indig asks, are patients being... Read more »
-
Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:CBST) said late yesterday afternoon that it has settled patent litigation related to its only marketed drug, the antibiotic daptomycin (Cubicin), with Teva Pharmaceutical. The... Read more »
-
There’s been some buzz on the Web in recent weeks about Follica’s technology for treating one of the most common maladies of aging in men—male pattern baldness. The company, which got... Read more »
-
Vertex Pharmaceuticals (NASDAQ:VRTX) reported today positive results from an ongoing late-stage study of its cystic fibrosis drug, VX-770, that show that the drug is working about as well in... Read more »
-
BL Healthcare, a Foxboro, MA-based provider of telemedicine products, has raised an additional $2 million in equity, debt, and rights financing to bring its Series A round to $4.9 million, according... Read more »
-
PerkinElmer (NYSE:PKI), the Waltham, MA-based provider of products and services focused on the health and safety of people and the environment, said today that it has inked a definitive... Read more »
-
Wilmington, MA-based SensAble Technologies, a maker of 3D modeling and haptic systems, has raised $2 million of a planned $6 million equity round of financing, according to an SEC filing.... Read more »
-
Expect to hear more about the vaccine developer VBI this year. The company has made some progress in addressing a major bugaboo in the vaccine field—the need to keep the vast... Read more »
-
Peptimmune, a Somerville, MA, biotech firm that has been developing a long-lasting drug for multiple sclerosis, filed for Chapter 7 liquidation on Monday, according to a court filing. VentureWire reported the... Read more »
-
A week after settling litigation related to the patents on gene-silencing treatments, Alnylam Pharmaceuticals and others have found themselves in another legal battle over the Tuschl patents related to RNA-interference treatments.... Read more »
-
Cloud Technology Partners, a Boston-based consulting firm, says that it has acquired Global Green Consulting Group. Financial terms of the deal weren’t announced. Global Green Consulting Group’s services will become part... Read more »
-
Lexington, MA-based Curis (NASDAQ:CRIS) said this morning that its partner Genentech of South San Francisco informed the firm that its pivotal Phase II study of a drug dubbed vismodegib... Read more »
-
Synageva BioPharma has nabbed $25 million in private equity financing as the Lexington, MA-based firm makes progress with its pipeline of treatments for rare diseases—an area that seems to be white... Read more »
-
Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ:ALNY) has been working with Tekmira Pharmaceuticals (TSE:TKM) of Vancouver, BC, since at least 2006 on getting its gene-silencing drugs into cells to... Read more »
-
The FDA said it has set April 28 as the date of an advisory committee meeting on Cambridge, MA-based Vertex Pharmaceuticals’ (NASADAQ:VRTX) application for approval of its experimental hepatitis... Read more »
-
Ariad Pharmaceuticals (NASDAQ:ARIA), a Cambridge, MA-based developer of cancer drugs against specific biological targets, said today that it has taken its option to co-promote its experimental drug ridaforolimus with... Read more »
-
Here’s an interesting development involving figures in the medical devices scenes of Boston and San Diego. Topera Medical, a secretive startup launched in 2008 in San Diego, has established a new... Read more »
-
[Updated 3/15/11, 2:28 pm ET. See note below] Litigation concerning key patents involved in the development gene-silencing drugs known as RNA-interference therapies has been settled. Cambridge, MA-based Alnylam Pharmaceuticals... Read more »
-
Edimer Pharmaceuticals wants to break new ground in the treatment of patients with an ultra-rare genetic disorder called X-linked hypohidrotic ectodermal dysplasia, or XLHED. And the small venture-backed operation based in... Read more »
-
There’s some bad news from Cambridge, MA-based Tolerx today. The venture-backed biotech firm and its partner GlaxoSmithKline (NYSE:GSK) reported that their experimental drug for Type 1 diabetes failed to... Read more »
Page 2 of 55 « previous page · next page »
